Recent Finacing
Recent Raise
Targanta develops oritavancin, an antibacterial candidate for cSSSI, completing two Phase 3 trials, engaging the FDA pre‑NDA, and planning trials for pneumonia, bacteremia, and single‑dose cSSSI.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors